Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

Graham David J.; Reichman Marsha E.; Wernecke Michael; Zhang Rongmei; Southworth Mary Ross; Levenson Mark; Sheu Ting-Chang; Mott Katrina; Goulding Margie R.; Houstoun Monika; MaCurdy Thomas E.; Worrall Chris; Kelman Jeffrey A.

首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

【24h】

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

机译：用于非衰弱性心房颤动的Dabigatran或Warfarin治疗的老年人医疗保险患者的心血管，出血和死亡率风险

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background-The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established.

机译：背景技术尚未建立达比替兰兰兰兰兰兰对的比较安全性，用于治疗一般实践环境中的非衰弱性颤动。

著录项

来源
《Circulation: An Official Journal of the American Heart Association》 |2015年第2期|共8页
作者
Graham David J.; Reichman Marsha E.; Wernecke Michael; Zhang Rongmei; Southworth Mary Ross; Levenson Mark; Sheu Ting-Chang; Mott Katrina; Goulding Margie R.; Houstoun Monika; MaCurdy Thomas E.; Worrall Chris; Kelman Jeffrey A.;
展开▼
作者单位

US FDA Off Surveillance &

Epidemiol Ctr Drug Evaluat &

Res Silver Spring MD USA;

US FDA Off Surveillance &

Epidemiol Ctr Drug Evaluat &

Res Silver Spring MD USA;

Acumen LLC Burlingame CA USA;

US FDA Off Biostat Ctr Drug Evaluat &

Res Silver Spring MD USA;

US FDA Off New Drugs Ctr Drug Evaluat &

Res Silver Spring MD USA;

US FDA Off Biostat Ctr Drug Evaluat &

Res Silver Spring MD USA;

Acumen LLC Burlingame CA USA;

US FDA Off Surveillance &

Epidemiol Ctr Drug Evaluat &

Res Silver Spring MD USA;

US FDA Off Surveillance &

Epidemiol Ctr Drug Evaluat &

Res Silver Spring MD USA;

US FDA Off Surveillance &

Epidemiol Ctr Drug Evaluat &

Res Silver Spring MD USA;

Acumen LLC Burlingame CA USA;

Ctr Medicare Serv Washington DC USA;

Ctr Medicare Serv Washington DC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词
anticoagulant; pharmacoepidemiology; safety; thrombin inhibitor; warfarin;

机译：抗凝血剂;药物杂散学;安全;凝血酶抑制剂;华法林;

相似文献

外文文献
中文文献
专利

1. Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation" [J] . Lavine Jay B. Circulation: An Official Journal of the American Heart Association . 2015,第14期

机译：Lavine关于文章“用达比加群或华法林治疗的非瓣膜性心房颤动的老年医疗保险患者的心血管，出血和死亡风险”的信函
2. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation [J] . Graham David J., Reichman Marsha E., Wernecke Michael, Circulation: An Official Journal of the American Heart Association . 2015,第2期

机译：用于非衰弱性心房颤动的Dabigatran或Warfarin治疗的老年人医疗保险患者的心血管，出血和死亡率风险
3. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation (vol 176, pg 1662, 2016) [J] . Graham JAMA internal medicine . 2016,第11期

机译：用达比加群或利伐沙班治疗的非瓣膜性心房颤动的老年医疗保险受益人中风，出血和死亡率风险（第176卷，第1662页，2016年）
4. Warfarin Underuse for Nonvalvular Atriai Fibrillation: How to Adjust Our Aims? [C] . G. DI PASQUALE, E. CERE, A. LOMBARDI International Workshop on Cardiac Arrhythmias . 2004

机译：Warfarin Filluse for Nonvalular Atriai颤动：如何调整我们的目标？
5. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
6. Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists [O] . Géric Maura, Pierre-Olivier Blotière, Kim Bouillon, -1

机译：达比加群或利伐沙班与维生素K拮抗剂新治疗的非瓣膜性心房颤动患者近期出血和动脉血栓栓塞事件风险的比较
7. Bleeding-Related Hospital Admissions and 30-Day Re-Admissions in Patients with Nonvalvular Atrial Fibrillation Treated with Dabigatran versus Warfarin [O] . Lau, Wallis C Y, Li, Xue, Wong, Ian C K, 2017

机译：达比加群与华法林治疗非瓣膜性心房颤动患者出血相关的住院和30天再入院

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

摘要

著录项

相似文献

相关主题

期刊订阅